22 June 2009: NorDiag has fully automated the process from swabs to the set up of the BD (Becton Dickinson) ProbeTec (TM) ET System. NorDiags "Bullet" instrument has the capacity up to 100 000 isolations per year. The clinical trial has been executed at Ullevaal Universityhospital in Norway.

The trial compared NorDiag's automated sample preparation solution for sexually transmitted infections with the BD ProbeTec ET Chlamydia trachomatis manual sample preparation. The tests (detection) were run on the BD ProbeTec ET System and used the BD ProbeTec ET Chlamydia trachomatis Amplified DNA Assay. The results of the clinical trial met the criterion.

"This widens our product offering and increases revenue potential for our company. It is the backbone for the IVD/CE marking. We are able to offer to ProbeTec ET users a unique automated system for both urine and swab sample preparation, says Mårten Wigstøl, CEO in NorDiag".

Contact:
CEO Mårten Wigstøl,
phone +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 31 man years. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the notice in Norwegian here